Currently, there is no cure for multiple myeloma, but there are treatment options that can help people with the disease live longer, healthier lives. Stem cell transplant is a standard of care for eligible patients. However, over half of those who are newly diagnosed with multiple myeloma are not eligible for transplant due to age or other major health problems, such as heart, lung, liver, or kidney disease.

In this interactive session, faculty will introduce a case study after which learners should be able to:

1. Discuss first- and second-line therapy for patients who are ineligible for transplants.
2. Discern the difference between administering subcutaneous daratumumab vs the IV form.
3. Describe how to administer subcutaneous daratumumab.

REGISTER   VIEW AGENDA

This activity is developed through a collaboration between The Association of Community Cancer Centers and The Leukemia & Lymphoma Society.